Sangamo partners with Pfizer to develop gene therapy for ALS – Reuters
Reuters |
Sangamo partners with Pfizer to develop gene therapy for ALS
Reuters The agency last month approved Spark Therapeutics Inc’s treatment for a rare form of blindness, marking the first approval of a gene therapy for an inherited disease. Under the terms of the deal, Sangamo will receive a $12 million upfront payment from … Sangamo, Pfizer Collaborate On Zinc Finger Protein Gene Therapy For ALSNasdaq Sangamo teams up with Pfizer to develop gene therapy to treat ALS; shares ahead 4% premarketSeeking Alpha Sangamo, Pfizer to Develop Gene Therapy for Neurodegenerative DisordersFox Business Endpoints News all 5 news articles » |
Genetic Literacy Project |
Should patients—not the FDA— have final say on risky gene therapy …
Genetic Literacy Project Working with mice, researchers have used gene therapy to restore sight to the blind, reprogram the body’s own T cells to attack cancerous tumors, prevent t. |